AABB Releases Findings From 2021 Platelet Survey

June 09, 2021

AABB released a graphic summary of findings from the 2021 AABB Platelet Survey, conducted to better understand the impact of the Food and Drug Administration guidance on bacterial risk control strategies on platelet availability and to evaluate the adoption of various risk control strategies. A total of 272 hospitals and 22 blood centers completed the survey, conducted March 23 - April 5.

The three most preferred mitigation strategies among the respondents were pathogen-reduced single-donor platelets (SDP) pathogen reduction technology (PRT) in platelet additive solution (PAS) (133 respondents), large-volume delayed sampling (LVDS) 48 for 7-day storage (45 respondents), and PRT in plasma (38 respondents). The three most offered mitigation strategies among the blood centers were LVDS 48 for 7-day storage (15 respondents), LVDS 36 for 5-day storage (10 respondents), and PRT in plasma (9 respondents). The three preferred mitigation strategies among the hospital-based blood centers were LVDS 48 with 7-day storage (11 respondents), PRT in plasma (7 respondents) and rapid tests (4 respondents). 

A total of 86% of respondents were aware that their hospital transfusion services are required to be FDA registered or licensed to extend the dating of platelets beyond day 5. Furthermore, 71.7% of hospitals were already FDA registered or licensed and 32.8% of hospitals were already compliant with the FDA guidance. 

Projected demand for all platelets exceeded supply except for LVDS 48 for 7-day storage. Some larger hospitals want to use secondary testing to expand their platelet options, but these mitigation strategies are not available from most blood centers. Some assumptions were taken to calculate the projected demand and supply. The extent of variability due to non-response and data extrapolation is difficult to assess.

Please contact Srijana Rajbhandary, BDS, MPH, AABB’s director of research, with any questions.